The Drug-Induced Respiratory Disease Website and App

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.n ILD with a granulomatous component

I. Interstitial/parenchymal lung disease

I.x Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)

I. Interstitial/parenchymal lung disease

I.aa An area or areas of consolidation

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.d Alveolar hemorrhage, diffuse (ANCA-positive/-related)

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

VI. Pleural and/or pericardial involvement

VI.d Pleural/pericardial effusion, ANA positive (DI lupus)

VI. Pleural and/or pericardial involvement

VI.m Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.j Phrenic nerve injury - Hemi- or bilateral diaphragmatic paralysis

X. Systemic/Distant conditions, syndromes and reactions

X.b Antiphospholipid antibodies w/wo the APL syndrome

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.e Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)

X. Systemic/Distant conditions, syndromes and reactions

X.l Myopathy-Myositis-Polymyositis (see also under Xba)

X. Systemic/Distant conditions, syndromes and reactions

X.m Sarcoid-like granulomatosis (endo-/extrathoracic)

X. Systemic/Distant conditions, syndromes and reactions

X.u Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

XII. Cardiovascular involvement / toxicity

XII.a Left or biventricular dysfunction/failure

XII. Cardiovascular involvement / toxicity

XII.s Heart failure (biventricular, congestive)

XVI. Imaging

XVI.e Imaging: Pulmonary opacities with a subpleural distribution

XVI. Imaging

XVI.k Imaging: An area or areas of consolidation

XIX. Pathology

XIX.a Path: NSIP-cellular pattern (see also Ia, Ib)

XIX. Pathology

XIX.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XIX. Pathology

XIX.f Path: ILD with a granulomatous component (see also Im)

XX. Infections & related conditions

XX.a Respiratory tract infection incl. pneumonia

XX. Infections & related conditions

XX.b Opportunistic pulmonary/systemic infections

XX. Infections & related conditions

XX.c Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)

XX. Infections & related conditions

XX.e Pneumocystis jiroveci pneumonia

XX. Infections & related conditions

XX.f Tuberculosis, miliary

XX. Infections & related conditions

XX.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

XX. Infections & related conditions

XX.y Histoplamosis (reactivation)

XX. Infections & related conditions

XX.z Coccidioidomycosis

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.l Lung nodule or nodules

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.ak Shrinking lung syndrome

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

IV. Airway involvement

IV.ab Cough (lone)

VI. Pleural and/or pericardial involvement

VI.d Pleural/pericardial effusion, ANA positive (DI lupus)

VI. Pleural and/or pericardial involvement

VI.m Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

VIII. Mediastinal involvement

VIII.a Lymphadenopathy (intrathoracic)

X. Systemic/Distant conditions, syndromes and reactions

X.a DRES syndrome - DRESS-like reaction

X. Systemic/Distant conditions, syndromes and reactions

X.b Antiphospholipid antibodies w/wo the APL syndrome

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.e Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

X. Systemic/Distant conditions, syndromes and reactions

X.o Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

X. Systemic/Distant conditions, syndromes and reactions

X.q Neutrophilic dermatosis (Pyoderma, Sweet syndrome)

X. Systemic/Distant conditions, syndromes and reactions

X.u Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

X. Systemic/Distant conditions, syndromes and reactions

X.x Systemic eosinophilic syndrome w/wo vasculitis (see also Xa)

X. Systemic/Distant conditions, syndromes and reactions

X.al Polyarteritis nodosa-like condition

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XI. Miscellaneous

XI.c Pleuritic chest pain

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XII. Cardiovascular involvement / toxicity

XII.d Myocarditis (can be fulminant)

XII. Cardiovascular involvement / toxicity

XII.au Giant cell myocarditis

XVI. Imaging

XVI.e Imaging: Pulmonary opacities with a subpleural distribution

XVII. Distinctive patterns - 'Eye-catchers'

XVII.w Eye catcher: Pseudocyanosis

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.b BAL: An excess proportion of neutrophils

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.c BAL: An excess proportion of eosinophils

XIX. Pathology

XIX.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

XIX. Pathology

XIX.e Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

XIX. Pathology

XIX.ay Path: Pulmonary vasculitis other than capillaritis

XIX. Pathology

XIX.az Path: Granulomatous pulmonary vasculitis

XIX. Pathology

XIX.bb Path: Eosinophilic vasculitis

XIX. Pathology

XIX.ct Path: Brownish macrophages in airspaces (airways - alveoli)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.n ILD with a granulomatous component

I. Interstitial/parenchymal lung disease

I.p Focal/localized area of pneumonitis/fibrosis

I. Interstitial/parenchymal lung disease

I.z Progression, acceleration or exacerbation of preexisting ILD/fibrosis

I. Interstitial/parenchymal lung disease

I.ae Radiation recall pneumonitis

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.h Major/massive hemoptysis

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.l Alveolar hemorrhage, localized (e.g. lobar)

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

IV. Airway involvement

IV.c Exacerbation or deterioration of preexisting asthma

IV. Airway involvement

IV.d Exacerbation or deterioration of preexisting COPD

IV. Airway involvement

IV.j Bronchiectasis

IV. Airway involvement

IV.l Large airway inflammation - Tracheitis (w/wo tissue eosinophilia)

IV. Airway involvement

IV.t Eosinophilic airway disease (asthma, bronchitis, bronchiolitis)

IV. Airway involvement

IV.u Sptutum production - Bronchorrhea - 'Bronchitis'

IV. Airway involvement

IV.w Bronchiolitis (a clinical-imaging pattern suggestive of)

IV. Airway involvement

IV.x Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)

IV. Airway involvement

IV.ab Cough (lone)

IV. Airway involvement

IV.af Sputum production - Bonchorrhea - ‘Bronchitis’

IV. Airway involvement

IV.ag Obstructive airway dysfunction (see also IVc, XVx)

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.g Vocal cord paresis/paralysis

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.r Tongue involvement (edema, glossitis, hematoma)

VI. Pleural and/or pericardial involvement

VI.m Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

VII. Pulmonary vasculopathy

VII.a Pulmonary embolism - Venous thrombosis/thromboembolism

VII. Pulmonary vasculopathy

VII.b Pulmonary arterial hypertension

VIII. Mediastinal involvement

VIII.a Lymphadenopathy (intrathoracic)

VIII. Mediastinal involvement

VIII.e Granulomatous mediastinal lymphadenopathy

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.r Myasthenia gravis - Myasthenic-like syndrome

X. Systemic/Distant conditions, syndromes and reactions

X.b Antiphospholipid antibodies w/wo the APL syndrome

X. Systemic/Distant conditions, syndromes and reactions

X.c Capillary leak syndrome (CLS)

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

X. Systemic/Distant conditions, syndromes and reactions

X.l Myopathy-Myositis-Polymyositis (see also under Xba)

X. Systemic/Distant conditions, syndromes and reactions

X.m Sarcoid-like granulomatosis (endo-/extrathoracic)

X. Systemic/Distant conditions, syndromes and reactions

X.o Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

X. Systemic/Distant conditions, syndromes and reactions

X.u Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

X. Systemic/Distant conditions, syndromes and reactions

X.aj Granulomatosis with polyangiitis (typically ANCA pos.) - GPA flare

X. Systemic/Distant conditions, syndromes and reactions

X.ap Cytokine release syndrome - Cytokine storm

X. Systemic/Distant conditions, syndromes and reactions

X.ax Connective tissue disease

X. Systemic/Distant conditions, syndromes and reactions

X.ay Scleroderma

X. Systemic/Distant conditions, syndromes and reactions

X.az Polymyalgia rheumatica

X. Systemic/Distant conditions, syndromes and reactions

X.bj Temporal arteritis (Horton’s)

XI. Miscellaneous

XI.e Metabolic acidosis (incl. lactic acidosis/-gap). May cause hyperpnea/dyspnea

XI. Miscellaneous

XI.l Neutropenia, agranulocytosis (w/wo infection/sepsis)

XII. Cardiovascular involvement / toxicity

XII.a Left or biventricular dysfunction/failure

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XII. Cardiovascular involvement / toxicity

XII.d Myocarditis (can be fulminant)

XII. Cardiovascular involvement / toxicity

XII.s Heart failure (biventricular, congestive)

XII. Cardiovascular involvement / toxicity

XII.t Heart block (bundle branch- or AV-)

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XVI. Imaging

XVI.e Imaging: Pulmonary opacities with a subpleural distribution

XVI. Imaging

XVI.k Imaging: An area or areas of consolidation

XVI. Imaging

XVI.v Imaging: Centrilobular micronodules (can be diffuse)

XVI. Imaging

XVI.aa Imaging: A large nodule or a mass

XVI. Imaging

XVI.ak Imaging: A 'tree-in-bud' pattern

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.a BAL: An excess proportion of lymphocytes

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.b BAL: An excess proportion of neutrophils

XIX. Pathology

XIX.a Path: NSIP-cellular pattern (see also Ia, Ib)

XIX. Pathology

XIX.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

XIX. Pathology

XIX.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XIX. Pathology

XIX.e Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

XIX. Pathology

XIX.f Path: ILD with a granulomatous component (see also Im)

XIX. Pathology

XIX.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XIX. Pathology

XIX.al Path: Acute/subacute bronchiolitis (see also IVc, IVi)

XIX. Pathology

XIX.au Path: Airway inflammation

XIX. Pathology

XIX.co Path: Myocarditis

XIX. Pathology

XIX.cr Path: Myocardial vasculitis

XX. Infections & related conditions

XX.c Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)

XX. Infections & related conditions

XX.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

XX. Infections & related conditions

XX.o Nocardia pulmonary/systemic infection